Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ATC Clear all
Completed Not applicable Interventional Results available

Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)

NCT00400881
View directory record Official record
Conditions
Respiratory Failure
Interventions
automatic tube compensation
Other
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 23, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

NCT05882734
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
M1774, Cemiplimab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Santa Monica, California • Pittsburgh, Pennsylvania • Knoxville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Results available

IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC

NCT05059470
View directory record Official record
Conditions
Thyroid
Interventions
Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Recruiting Phase 1 Interventional

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

NCT06498973
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Tagraxofusp-erzs
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

NCT03661424
View directory record Official record
Conditions
Breast Cancer Female, Leptomeningeal Metastases
Interventions
HER2 BATs
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 23, 2026, 5:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 23, 2026, 5:50 AM EDT
Suspended Not applicable Interventional

Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)

NCT06672510
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
ATC
Device
Lead sponsor
Akura Medical
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Thousand Oaks, California • Hartford, Connecticut • Bradenton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

Exercise Training to Improve PTSD Symptoms and Health in Older Veterans

NCT04199182
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Exercise Training, Healthy Aging Attention Control (HA-ATC)
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Not listed Phase 1 Interventional

NVD-003 in the Treatment of Congenital Pseudarthrosis of the Tibia

NCT05693558
View directory record Official record
Conditions
Congenital Pseudarthrosis of Tibia
Interventions
NVD-003, an autologous 3D scaffold free osteogenic graft
Biological
Lead sponsor
Novadip Biosciences
Industry
Eligibility
2 Years to 8 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 23, 2026, 5:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
RP-3500, Olaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 23, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

NCT05001737
View directory record Official record
Conditions
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
6 Months to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Not listed Phase 2 Interventional

MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia

NCT04887311
View directory record Official record
Conditions
Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children, Ataxia Telangiectasia
Interventions
MBM-01
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 23, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effect of Doxycycline in Patients With Amyloidosis

NCT01677286
View directory record Official record
Conditions
Amyloidosis
Interventions
Doxycycline 100 mg po bid x 12 months
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 23, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

NCT00972075
View directory record Official record
Conditions
Non-24 Hour Sleep-Wake Disorder, Blindness
Interventions
melatonin (Circadin), placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
20 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 23, 2026, 5:50 AM EDT
Recruiting Phase 4 Interventional

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

NCT06049680
View directory record Official record
Conditions
Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
Interventions
SMOFlipid® (lipid injectable emulsion)
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
1 Month to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

Matching Treatments to Cognitive Deficits in Offenders With Substance Use Disorders

NCT06981351
View directory record Official record
Conditions
Antisocial Behavior
Interventions
Attention to Context (ATC) training, Affective Cognitive Control (ACC) training
Behavioral
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

NCT03022409
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Ceralasertib, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 23, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

NCT05002140
View directory record Official record
Conditions
Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions
XRD-0394, Palliative radiotherapy
Drug · Radiation
Lead sponsor
XRad Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 23, 2026, 5:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

NCT05691491
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Temozolomide, Tuvusertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Irvine, California • La Jolla, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Withdrawn Phase 1 Interventional

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

NCT05341947
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Activated T cells
Biological
Lead sponsor
Jeremy Rudnick, M.D
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 23, 2026, 5:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

NCT03272334
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
HER2 BATs with Pembrolizumab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Terminated Not applicable Interventional

Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia

NCT02246491
View directory record Official record
Conditions
Ataxia-Telangiectasia (A-T)
Interventions
A-T iPS cell line, Carrier patients iPS cell line
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 23, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

NCT06518564
View directory record Official record
Conditions
Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
Interventions
Avelumab, M1774
Drug
Lead sponsor
Panagiotis Konstantinopoulos, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 23, 2026, 5:50 AM EDT
Completed No phase listed Observational

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

NCT04898751
View directory record Official record
Conditions
Cutaneous Toxicity From ICI Therapy
Interventions
Immune checkpoint inhibitor (ICI)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
2,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 23, 2026, 5:50 AM EDT